Skip to main content

Leadership

News Release

Printer Friendly Version View printer-friendly version
Download PDF Download PDF
<< Back
Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA
112,000-Square-Foot Baltimore Facility Is Designed to Enable Surge Manufacturing of Medical Countermeasures to Address Urgent Public Health Threats

ADVISORY, May 09, 2017 (GLOBE NEWSWIRE) --

WHO: Emergent BioSolutions Inc. (NYSE:EBS) 
   
WHAT: Ribbon-cutting and tour of expanded Emergent BioSolutions’ Center for 
  Innovation in Advancement Development and Manufacturing (CIADM), 
  featuring speakers:
   
  Daniel J. Abdun-Nabi
  President & Chief Executive Officer, Emergent BioSolutions
   
  Rick A. Bright, Ph.D.
  Director, Biomedical Advanced Research and Development Authority (BARDA)
  Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness 
  and Response at the U.S. Department of Health and Human Services (HHS)
   
  William H. Cole
  President & CEO, Baltimore Development Corporation
   
  Secretary Mike Gill
  Department of Commerce, State of Maryland
   
WHY: Five years ago, Emergent and BARDA entered into a public-private partnership 
  to establish a CIADM intended to develop and manufacture medical 
  countermeasures to protect the public in health emergencies. 
   
  This Wednesday, Emergent will unveil its newly expanded Baltimore CIADM 
  facility – one of only three HHS-designated Centers in the United States. The 
  112,000-square-foot facility, comprised of laboratory, manufacturing and office 
  space, offers flexible manufacturing of drug substance from microbial, cell 
  culture, or viral production platforms. Its capabilities for advanced 
  development and manufacturing of medical countermeasures were designed to 
  help address the U.S. government’s national security and public health needs. 
  The facility is equipped with disposable manufacturing technology to enable 
  Emergent to meet the government’s domestic preparedness priorities and 
  needs on a cost-effective, reliable and sustainable basis. 
   
  Since its inception, the Emergent CIADM has been awarded four task orders by 
  BARDA to develop Ebola and Marburg therapeutics and a Zika vaccine. 
  Emergent has also successfully manufactured some of its product candidates 
  at the CIADM and an Ebola vaccine candidate as part of a third-party 
  collaboration.
   
WHERE: Emergent BioSolutions Bayview Campus
  5901 East Lombard St.
  Baltimore, MD 21224
   
WHEN: Wednesday, May 10, 2017
  9 a.m. to 11 a.m.

                      
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
kiefferl@ebsi.com

Primary Logo

Emergent BioSolutions Inc.